mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression
17.11.2010
Huber TB, Walz G, Kuehn EW.
Kidney Int. 2011;79(5):502-11
Studies using rapamycin in animal models of kidney disease indicate that mTOR deregulation has a role in glomerular disease, polycystic kidney disease, and renal cancer. The role of mTOR activation in podocytes is context dependent, and indirect evidence suggests that mTOR may have a role in chronic podocyte loss.
